Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | HTR1B | P28222 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15808499 | 0.86 | KDM4E (0.73) | ALDH1A1MAPTCHRM4TSHR | |
| SCHEMBL6184356 | 0.84 | NPSR1 (0.61) | NPSR1ALDH1A1USP2HPGDHTR1A | |
| SCHEMBL2469546 | 0.84 | ALDH1A1 (0.86) | NPSR1ALDH1A1USP2HPGDMAPT | |
| SCHEMBL29675228 | 0.84 | ALDH1A1 (0.86) | NPSR1ALDH1A1USP2HPGDMAPT | |
| SCHEMBL13746186 | 0.84 | NPSR1 (0.72) | NPSR1ALDH1A1USP2HPGDMAPT | |
| SCHEMBL22462992 | 0.84 | NPSR1 (0.81) | NPSR1ALDH1A1USP2HPGDMAPT | |
| SCHEMBL18829414 | 0.81 | ALDH1A1 (1.00) | NPSR1ALDH1A1USP2HPGDHTR1A | |
| SCHEMBL6244724 | 0.81 | ALDH1A1 (0.93) | NPSR1ALDH1A1USP2HPGDHTR1A | |
| SCHEMBL30475533 | 0.80 | ALDH1A1 (0.73) | NPSR1ALDH1A1USP2HPGDMAPT | |
| SCHEMBL20148016 | 0.80 | NPSR1 (0.68) | NPSR1ALDH1A1USP2HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759342-B2 | Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| EP-1501467-A4 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20080039454-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
| EP-1501467-A2 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | Bristol-Myers Squibb Company (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003088908-A2 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039454-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, NTSR2 | NPSR1 55/4885ALDH1A1 4139/4885USP2 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.